Precision radiation takes on liver cancer: could SABR beat standard care?
NCT ID NCT07628751
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study compares a precise radiation technique called SABR against standard treatments (like heat probes or chemo injections) for early-stage liver cancer. About 218 adults with a single tumor up to 8 cm will be randomly assigned to SABR or standard care. The main goal is to see if SABR better prevents the cancer from growing back in the treated area over two years.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Stereotactic Ablative Body Radiotherapy (SABR)
- What this could lead to
- If SABR works better, it could become a new standard, non-invasive treatment option for early liver cancer, potentially improving local control and survival.
- What could go wrong
- This is a Phase 2 trial with 218 participants, so results are still early. SABR may not prove superior to standard care, and side effects from radiation are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EARLY HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Trans Tasman Radiation Oncology Group
RECRUITINGWaratah, Australia
-
University Health Network - Princess Margaret Cancer Centre
RECRUITINGToronto, Ontario, M5G 2M9, Canada